Reach Us 44-7480022765
Editor - Maria Angelica Cortez | The University of Texas MD Ande | 24863
ISSN: 2471-2671

Archives of Surgical Oncology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

World Congress on Women Oncology & Care

Tokyo, Japan

32nd International Oncology Conference

Berlin, Germany

4th Global Expo on Cancer and Oncology Research

Osaka, Japan
Share This Page

Maria Angelica Cortez

Maria Angelica Cortez
Maria Angelica Cortez
The University of Texas MD Anderson Cancer Center
Houston, Texas


From an early age, I have had both a curious nature and a passion to reduce human affliction, and these traits led me to a career in oncology research. Since 2004, I have been focusing on the identification of novel drug targets for cancer. During my Master’s and Ph.D program at University of Sao Paulo, one of the most prestigious academic centers in Brazil, I focused on mechanisms of resistance to standard chemotherapy in acute Leukemias and the molecular pathways underlying Glioblastoma tumorigenesis. Upon completing my Ph.D. program, I was recruited to MD Anderson to pursue analogous translational research projects. As a postdoctoral fellow at MD Anderson Cancer Center, I was afforded the opportunity to explore cutting-edge science in exciting and novel areas of microRNA and long non coding RNAs with potential roles in cancer at Dr. George Calin’s lab. Since 2011, I joined Dr. James Welsh’s laboratory to explore new mechanisms of tumor immune evasion and identification of new potential therapeutic targets to overcome resistance to immunotherapies in combination with standard therapies such as radiation.

Research Interest

My expertise lies in mechanisms of cancer, validating potential cancer targets in vitro and in vivo and translating this potential into future medicines.